Location History:
- Fukushima, JP (2012)
- Iwaki, JP (2013)
- Chuo-ku, JP (2023)
Company Filing History:
Years Active: 2012-2023
Title: Koichi Nonaka: Innovator in Protein Production
Introduction
Koichi Nonaka is a prominent inventor based in Iwaki, Japan. He has made significant contributions to the field of biotechnology, particularly in the area of protein production. With a total of 3 patents, Nonaka's work focuses on enhancing the efficiency of producing foreign proteins in host cells.
Latest Patents
One of his latest patents is titled "Promoter of Hspa5 gene." This invention provides an innovative approach to enhancing the production of foreign proteins that serve as pharmaceutical products in cultured mammalian cells. The invention includes transformed cells that possess a novel Hspa5 gene promoter, along with a method for secreting and producing foreign proteins at high levels using these transformed host cells.
Another significant patent is "Method for high-level secretory production of protein." This invention outlines a means for the high-level secretory production of proteins, particularly those with complex structures, such as antibodies, in host cells like yeast. The method involves using transformed host cells that contain one or more types of chaperone protein genes and suppressing the O sugar chain inherent to yeast cells.
Career Highlights
Throughout his career, Koichi Nonaka has worked with notable organizations, including Daiichi Sankyo Company, Limited and the National Institute of Advanced Industrial Science and Technology. His experience in these institutions has contributed to his expertise in biotechnology and protein production.
Collaborations
Nonaka has collaborated with esteemed colleagues, including Yasunori Chiba and Yoshifumi Jigami. These partnerships have further enriched his research and development efforts in the field.
Conclusion
Koichi Nonaka's innovative work in protein production has made a significant impact in biotechnology. His patents reflect a commitment to advancing the efficiency of producing essential pharmaceutical proteins.